SSA
XGN icon

Schonfeld Strategic Advisors’s Exagen XGN Stock Holding History

Schonfeld Strategic Advisors’s Portfolio XGN Stock Details XGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$61K Buy
20,333
+6,912
+52% +$26.7K ﹤0.01% 1945
2025
Q4 		$81.6K Buy
+13,421
New +$122K ﹤0.01% 1839

Other funds holding XGN

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.92% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $107M AUM
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
FCM
FourWorld Capital Management New York $196M AUM 42.39% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
MBAM
Mink Brook Asset Management West Palm Beach, Florida $179M AUM 37.68% 1-Year Est. Return

Schonfeld Strategic Advisors's XGN Position: Q1 2026 in Review

Schonfeld Strategic Advisors increased its Exagen (XGN) stake by 52% in Q1 2026, buying an estimated $26.7K and bringing the position to 20,333 shares worth $61K. The position accounts for ﹤0.01% of the portfolio, ranked #1945.

Schonfeld Strategic Advisors first reported a position in XGN in Q4 2025 and has held it in 2 quarters since. The position peaked at $81.6K in Q4 2025. 61 funds tracked by Wall St. Rank hold XGN as of Q1 2026.

  • Schonfeld Strategic Advisors held 20,333 shares of Exagen worth $61K as of Q1 2026.
  • Schonfeld Strategic Advisors bought 6,912 Exagen shares in Q1 2026, an estimated $26.7K.
  • Exagen made up ﹤0.01% of Schonfeld Strategic Advisors's portfolio in Q1 2026, its #1945 holding.
  • Schonfeld Strategic Advisors first reported a position in Exagen in Q4 2025 and has held it in 2 quarters since.
  • Schonfeld Strategic Advisors's Exagen position peaked at $81.6K in Q4 2025.
  • 61 funds tracked by Wall St. Rank held Exagen as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.